Stiripentol for primary hyperoxaluria in patients 6 and older
Part of Genetic & congenital, Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a medication called stiripentol to see if it can lower oxalate levels in people with primary hyperoxaluria (types 1, 2, or 3). It may help prevent kidney stones and protect kidney function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 6 years old or older.
- You have a confirmed diagnosis of primary hyperoxaluria (type 1, 2, or 3) by genetic testing.
- Your kidney function is at least 45 mL/min/1.73m².
- You are on standard treatments for this condition (like increased fluids, vitamin B6, potassium citrate, or lumasiran).
- You have not had a kidney or liver transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment for primary hyperoxaluria type 1, a rare condition that causes too much oxalate in the body, which can lead to kidney stones and kidney damage. The treatment is given as an injection, and the study will see if it is safe and how the body responds.
This study tests a new drug called YOLT-203 for people with primary hyperoxaluria type 1 (PH1), a rare genetic condition where the body produces too much oxalate, which can damage the kidneys. The trial aims to see if this drug can help reduce oxalate levels and prevent kidney damage.
This Phase 2 study tests a medicine called DCR-PHXC to lower body oxalate levels in people with PH1 who have advanced kidney failure. By lowering oxalate, the treatment may reduce harm from oxalate buildup and help researchers understand safety and effectiveness.
This trial tests an experimental drug called YOLT-203 for people with type 1 primary hyperoxaluria (PH1), a rare condition that causes high oxalate levels and can damage the kidneys. It aims to see if YOLT-203 can safely help manage the disease.
This trial tests a new treatment called ABO-101 for people with primary hyperoxaluria type 1, a rare disease that causes high oxalate levels in urine. The study aims to see if ABO-101 can lower oxalate and protect kidney function.
This trial studies how levels of oxalate (a substance linked to kidney stones) relate to vitamin C levels in your blood. It aims to improve lab testing for these substances.
Hear when a new Primary Hyperoxaluria Type 1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.